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Abstract
Transmission of HIV first results in an acute infection, followed by an apparently asymptomatic
period that averages ten years. In the absence of antiretroviral treatment, most patients progress
into a generalized immune dysfunction that culminates in death. The length of the asymptomatic
period varies, and in rare cases infected individuals never progress to AIDS. Other individuals
whose behavioral traits put them at high-risk of HIV transmission, surprisingly appear resistant and
never succumb to infection. These unique cases highlight the fact that susceptibility to HIV infection
and progression to disease are complex traits modulated by environmental and genetic factors.
Recent evidence has indicated that natural variations in host genes can influence the outcome of
HIV infection and its transmission. In this review we summarize the available literature on the roles
of cellular factors and their genetic variation in modulating HIV infection and disease progression.
Background
The period of asymptomatic disease after HIV-1 infection
averages about ten years, although it may vary greatly
among infected subjects [1]. The existence of attenuated
viral strains that fail to induce disease in animal models
has long been known. Similarly, it is now widely accepted
that human allelic variants for certain genes can influence
the susceptibility to HIV-1 infection [2,3]. Supporting a
role for genetic factors in the host, several studies have
shown that susceptibility to HIV-1 in vitro largely varies
among individual donors. Conversely, primary cells from
homozygotic twins display much less variation in their
permissivity to infection [4-8].
Like all viruses, HIV-1 must usurp the cellular machinery
at multiple steps to complete a productive cycle. The virus
enters cells by fusing with the cellular membrane, taking
advantage of receptor and co-receptor host proteins,
which otherwise play important roles in immunity and
inflammation. Then, the viral genetic material is delivered
into the cytoplasm in the form of a nucleoprotein core.
The viral RNA genome is copied into DNA, transported to
the cell nucleus, and integrated in the host chromosome.
The proviral HIV-1 DNA is transcribed into viral mRNAs,
which are then processed and exported to the cytoplasm.
Upon translation, viral products are transported to bud-
ding sites where virions are assembled together with viral
RNA. For each of these steps, HIV-1 relies on cellular pro-
teins. Only a fraction of these host proteins have been
identified, but their role in the HIV-1 life cycle is currently
a subject of intense investigation.
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Approaches to study HIV disease progression
Several approaches have been used to study HIV patho-
genesis in vivo. The availability of non-human primate
models has largely advanced our understanding of the
field. Studies with animal models have highlighted the
importance of the so-called viral "accessory genes" in HIV
disease progression. These genes were initially deemed
non-essential in in vitro studies because the virus would
be able to replicate despite their removal from the viral
genome [9]. Despite the usefulness of animal models to
define viral determinants of pathogenesis, the genetic dif-
ferences between human and non-human primates, have
made the latter less amenable for the study the role of host
factors.
Long-term nonprogressors (LTNP) have provided a
unique opportunity to study the mechanisms of HIV dis-
ease. LTNPs are HIV-infected individuals who have lived
free of symptoms for extended periods of time, in the
absence of antiretroviral treatment. A standard criterion
for LTNP status is to have had a documented infection for
ten years or more, stable CD4-positive T cell counts above
500 cells/ml, and plasma viral load below 10,000 RNA
copies/ml. Depending on the definition of "nonprogres-
sion" used, this population has been estimated to repre-
sent 2–4% of all infected patients [10]. The recruitment of
LTNP cohorts is a formidable task, because until recently,
most patients with well documented clinical histories had
been treated before the onset of symptoms.
An additional approach to examine disease progression is
to investigate highly exposed uninfected (EU) individuals.
EUs are subjects who resist HIV infection and seroconver-
sion, despite being at high-risk for transmission. EU
cohorts have been gathered from groups of intravenous
drug users (IDU), sex workers, children born to seroposi-
tive mothers, individuals performing unprotected sex
with multiple partners, and health care workers undergo-
ing accidental exposure to the virus [11].
Important insight into HIV pathogenesis can also be
gained by studying the natural course of infection in sero-
positive patients. Clinical variables (decline in CD4
counts, increase in viral load) have been used to monitor
the rate of progression to disease in untreated patients, or
to establish prognosis in terms of virologic and immuno-
logic success in patients following antiretroviral regimes.
These variables can be statistically associated with host
genotypic variants or specific phenotypic traits.
Finally, the study of healthy HIV-seronegative patients
who may bear genetic markers of interest, can also shed
light into the mechanisms of HIV pathogenesis. The role
of cellular factors influencing HIV replication and immu-
nity can be addressed by exposing primary cells from
healthy seronegative individuals to virus in vitro. Like-
wise, statistical associations between haplotypes or single-
nucleotide polymorphisms (SNP) can be drawn by mon-
itoring the extent of viral replication in vitro. When avail-
able, genetic associations with the rate of replication in
these ex-vivo models can also be validated with in vivo
data monitoring disease progression [12].
Factors influencing susceptibility to infection and the
course of disease can be grouped into three categories: 1)
viral factors determining the replicative properties of the
virus or its ability to escape immune responses; 2) cellular
factors modulating the innate or acquired immune
responses to infection; and 3) cellular factors co-operating
with viral products that govern the ability of the virus to
replicate in human cells. Thus, the rate at which an
untreated HIV-infected patient progresses to AIDS may be
explained by a combination of these factors, which ulti-
mately dictate how fast HIV replicates and/or how effi-
ciently it overcomes the immune defenses posed by the
host. Below, we will discuss cellular factors influencing
various steps of the HIV life cycle, and those modulating
the innate immune response. The role of the HLA system
in AIDS progression is beyond the scope of this review,
and has been amply discussed in other reviews [13-15].
Host factors modulating viral entry
The HIV-1 co-receptors: CCR5 and CXCR4
Entry into target cells occurs by a multi-step process that
culminates with the fusion of viral and cellular mem-
branes. HIV-1 utilizes CD4 as its primary receptor. Bind-
ing to CD4 is followed by conformational changes in the
viral envelope that lead to the engagement of one of the
viral co-receptors (CCR5 or CXCR4) [16]. Based on their
functionality in vitro, other chemokine receptors may also
work as HIV-1 co-receptors. Among them are CCR2,
CCR3, CCR8, CCR9, CXCR6, CX3CR1, ChemR23, APJ,
and RDC1. However, CCR5 and CXCR4 constitute the
major co-receptors in vivo (for a recent review see [17]).
CXCR4 was the first co-receptor identified [18]. After-
wards, the role of CCR5 in HIV-1 infection was soon elu-
cidated [19-23]. Soon after these findings, researchers
sought genetic polymorphisms that could confer protec-
tion to HIV-1 infection [19-21,23,24]. These studies char-
acterized the CCR5∆32 allele, which has been
unequivocally associated with protection to HIV-1 infec-
tion in homozygotic individuals [24-26]. This discovery
provided the first conclusive evidence for the existence of
genetic resistance to HIV-1 infection. CCR5∆32 expresses
a truncated co-receptor that is not transported to the cell
surface and thus is incompetent for viral entry [27]. Indi-
viduals homozygous for the ∆32 allele seem to have a nor-
mal life expectancy, although immunological differences
have been reported, which may influence the outcome ofRetrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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infections with other pathogens, such as West Nile and
hepatitis C virus (reviewed in [17,28]). The apparent lack
of immunological dysfunction in individuals with the
homozygous∆32 genotype may be explained by the func-
tional redundancy in the chemokine receptors and their
ligands. The CCR5∆32 allele occurs at a frequency of 4–
15% in the Caucasian population, with higher frequen-
cies in Northern European populations. However, the
CCR5∆32 allele is rarely found in Asians and Africans.
Approximately 1% of Caucasians carry two copies of the
∆32 allele [29]. These individuals are overrepresented in
cohorts of high-risk HIV-seronegative individuals (EUs)
[25,30,31]. Protection against HIV-1 infection in
homozygous CCR5∆32 individuals, however, is not com-
plete. Although rare, infections of homozygous CCR5∆32
have been reported, but always in patients infected with
virus strains utilizing the CXCR4 co-receptor [32-37].
Other studies have reported increased frequencies of
CCR5∆32 heterozygotes among LTNP, and in patients
progressing to disease at slower than normal rates [38-41].
However, these associations have not been observed in all
cohorts, suggesting that the CCR5∆32 allele alone may
not universally slow progression to AIDS [42-45]. Genetic
differences among the ethnicities evaluated, or different
transmission routes in the studied cohorts may explain
these discrepancies.
The observation that high level of CCR5 expression on
CD4-positive primary T cells is associated with high viral
loads and accelerated disease progression further high-
lights the contribution of CCR5 to disease progression
[46,47]. Generally, lymphocytes from ∆32 heterozygous
individuals express lower surface levels of CCR5, as com-
pared to those observed on cells from individuals
homozygous for the wild type gene [48]. In the previous
CCR5 expression in heterozygous individuals was lower
than the expected 50%, relative to wild-type homozygous.
This observation led the authors to hypothesize that the
truncated co-receptor may dimerize with the full-length
protein and interfere with its transport.
Other mutations in the CCR5 coding region have been
described. Some of them introduce frame-shifts that result
in truncated proteins that, similarly to the ∆32 variant, fail
to be transported to the cell surface (e.g., FS299). Other
mutations (e.g. C20S and C269F) affect the formation of
disulfide bridges, altering surface expression of the recep-
tor and the ability to bind ligands [49]. Some mutations
result in undetectable or very low levels of surface receptor
(C269F, G106R, C101X). Unlike ∆32, most of these CCR5
variants are relatively rare (frequencies below 1–2%) and
only present in specific populations. Thus, their role in
HIV-1 disease progression has not been properly estab-
lished [17,49,50]. Interestingly, the rare C20S, C101X
(also called m303), and T303A alleles are over-repre-
sented in EU individuals also carrying the more common
CCR5∆32 allele [51,52]. These findings suggest that alle-
les that may, in the context of a wild type allele, have a
weak effect, may exert a more profound protection in
combination with CCR5∆32.
Genetic variants have also been described in the CCR5
promoter. Most changes are single base substitutions that
could potentially alter the level of expression. CCR5P1,
one of the multi-site haplotypes identified in the CCR5
promoter, is composed of 13 distinct SNPs. This haplo-
type has been associated with faster progression to AIDS
in individuals carrying the wild type coding region for
CCR5 and CCR2, and homozygous for CCR5P1 [53]. A
similar association with rapid progression has been
reported for an A/G polymorphism located in the first
CCR5 intron. Individuals containing A in both copies
(59029-A/A) progress more rapidly to AIDS [54]. Interest-
ingly, the ∆32 phenotype seems to be largely influenced
by the presence of mutations in the CCR5 promoter
region, with some combinations resulting in poor co-
receptor expression and protection against HIV-1 trans-
mission [55].
Antibodies against CCR5 may provide another mecha-
nism of interference with CCR5 function in vivo. Anti-
CCR5 antibodies have been reported in a subset of LTNP
(24%) but not in other populations studied. These anti-
bodies induce internalization of the co-receptor in vivo
and block HIV entry of R5 strains in vitro [56]. Anti-CCR5
antibodies have also been detected in the milk of 66% and
83% of HIV-seronegative and seropositive women,
respectively. Anti-CCR5 antibodies purified from these
women also protect against infection of R5 strains in vitro
[57]. These findings suggest that some degree of protec-
tion against vertical transmission of HIV-1 may be medi-
ated by anti-CCR5 antibodies present in the milk. The
mechanism governing induction of anti-CCR5 antibodies
in humans is unknown, but these observations under-
score the interesting prospect of preventing HIV transmis-
sion with vaccines targeting the CCR5 co-receptor, an
approach that is being examined in murine models [58].
The compelling evidence supporting the role of CCR5∆32
in protection from disease in homozygous individuals,
the apparently healthy characteristics of these individuals,
and the ubiquitous presence of CCR5-tropic HIV-1 strains
throughout most of the disease, have prompted efforts to
target CCR5 with novel antiretroviral therapies. To date, at
least nine small-molecule inhibitors and monoclonal
antibodies are under development, being tested in clinical
trials, or awaiting imminent FDA review [59,60]. Aplavi-
roc, maraviroc, and vivriviroc are noncompetitive, allos-
teric CCR5 antagonists that have been tested in large
clinical trials. Unlike CCR5 agonists (e.g. PSC-RANTES),Retrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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none of these compounds induces signaling through
CCR5 or receptor internalization. There are potential
problems associated with the treatment with CCR5 antag-
onists. For example, use of this therapy may lead to the
emergence of CXCR4-tropic strains, which could acceler-
ate disease progression [61]. In addition, CCR5 inhibition
could interfere with the normal immune and inflamma-
tory responses. Despite the apparent normal phenotype of
CCR5∆32 homozygotic individuals, it is not clear how
interference with CCR5 will affect the already impaired
immune systems in HIV-infected patients. Thus, many
questions need to be answered before CCR5 inhibitors are
safely used in humans.
CCR2 and CX3CR1
Despite the pivotal role of CCR5 as the major co-receptor
for HIV-1, polymorphisms in other chemokine receptors
appear to also exert a certain degree of protection against
HIV-1 infection and/or disease progression. The most
compelling evidence comes from the CCR2-64I variant,
an allelic variant in which isoleucine 64 is replaced by
valine [62]. Heterozygous individuals for CCR2-64I
progress slower to AIDS, although no clear effect in pro-
tecting against HIV-1 infection has been documented. Not
all studies have confirmed this association [43,63], and
the effect of the CCR2-64I remains controversial. Intrigu-
ingly, the CCR2 receptor is used only by a few strains in
vivo, thus the mechanism of action of the CCR2-64I vari-
ant is unknown. CCR2 lies 17.5 kb upstream of the CCR5
promoter, and it has been suggested that the 64I variant
may be in linkage disequilibrium with genetic variations
in the CCR5 region [64]. To date, most reports have
observed no changes in the levels of CCR2 or CCR5 sur-
face expression in CCR2-64I individuals [64,65]. One
study, however, reported lower levels of surface CCR5 and
suggested, though it did not prove, that CCR2-64I may
bind with increased affinity to CCR5 intracellularly and
thus interfere with the expression of CCR5 at the cell sur-
face [66]. Another report suggested interference with
CXCR4 as an alternative explanation, demonstrating that
the 64I gene product dimerizes with CXCR4 more effi-
ciently than the wild-type CCR2 [67].
CX3CR1, the receptor for the chemokine fractalkine [68],
has also been associated with HIV-1 disease progression.
Its role as a co-receptor for HIV-1 in vivo is not clear, but
it has been suggested that CX3CR1 could affect HIV-1 rep-
lication by influencing the recruitment of immunomodu-
latory cells. Two SNPs have been identified that form part
of the haplotype I249-M280. Originally, this haplotype
was found at higher frequency in a cohort of Caucasian
HIV-infected patients progressing to AIDS faster than nor-
mal [69]. These results were later confirmed with a cohort
of HIV-infected children [70]. In another study evaluating
individuals entering HAART treatment during one year,
the I249 polymorphism was found at a higher frequency
among those displaying early immunological failure, esti-
mated as a decline in CD4 counts [71]. A study with a
Spanish cohort found the haplotype composed of I249
and T280 was overrepresented among LTNPs, as com-
pared to normal progressors, but the same study reported
no significant effect on the distribution of the M280 SNP
[72]. Adding controversy to the role of CX3CR1, the
results with the M280 SNP have not been confirmed in
other studies [73-75]. A possible explanation has been
proposed to explain these discrepancies, as follows. Due
to the deleterious effect of the M280 allele, this SNP may
have disappeared from some cohorts due to premature
death of patients before recruitment. The low frequency of
the allele observed in a French cohort supports this expla-
nation [76]. Additional studies will be needed to address
the importance of CX3CR1 in HIV-1 pathogenesis and to
understand the biological basis behind the observed phe-
notypes.
The phenotypic switch: Does co-receptor usage influence 
disease progression?
The HIV-1 strains that are most often responsible for
transmission utilize CCR5. These so-called M-tropic (R5)
viruses predominate during the asymptomatic stage and
infect CD4-positive lymphocytes and macrophages. In
approximately half of the patients with advanced disease,
the viral quasiespecies are dominated by viruses that uti-
lize CXCR4 [77]. These viruses are called T-tropic (or X4)
and infect macrophages inefficiently [78,79]. The emer-
gence of X4 viruses ("phenotypic switch") is associated
with accelerated decline in CD4-positive lymphocyte
counts and faster progression to disease. Thus, the pheno-
typic switch has been thought of as a causal factor leading
to accelerated disease. In support of a role for X4 viruses
in disease progression, studies with macaques infected
with SIV carrying CXCR4-tropic HIV-1 envelope (SHIV
chimera) display rapid loss of CD4 counts and develop
AIDS faster than the R5 counterpart [80].
It is possible that the emergence of X4 viruses may be the
consequence, rather than the cause of immune deteriora-
tion and disease progression [77]. Supporting this idea,
not all patients who develop full-blown AIDS experience
the switch to X4 viruses, and yet the R5 strains present in
these individuals late during disease are more pathogenic
than early viruses [81]. The mechanisms governing HIV
co-receptor switch are poorly understood. Furthermore, it
is not clear whether the so called "switch", emergence of
X4 tropic viruses, occurs by acquisition of mutations in R5
envelopes, or rather X4 viruses are transmitted during
infection but replicates poorly during the asymptomatic
stages. The emergence of viruses with dual tropism (R5-
X4) suggest the accumulation of gradual changes. More
sensitive phenotypic assays able to detect very small frac-Retrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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tions of X4 and dual-tropic viruses will allow us to under-
stand how viral tropism changes throughout infection.
Several selective forces have been suggested to explain
why the emergence of X4 strains is restricted during initial
phases of infection (reviewed in [82]). High levels of
CCR5-positive activated and memory cells present in gut-
associated lymphoid tissue, an important site during
acute infection, may provide fertile ground for the prolif-
eration of R5 tropic strains. In addition, the constitutive
levels of expression of SDF-1 in mucosal tissues could act
to restrict transmission of X4 viruses [83]. This, however,
contradicts the observation that parenteral transmission
of HIV-1 also results in the early predominance of R5
viruses. Clearly, some selective forces must keep X4
viruses under control at early stages of infection. Later in
infection, the selective pressure achieved by increased lev-
els of β-chemokines (active against R5 strains), and the
reduced levels of neutralizing antibodies to which X4
tropic viruses are more sensitive [84] may trigger the phe-
notypic switch. The observation that many pathogens are
potent inducers of HIV-suppressive β-chemokines sug-
gests that opportunistic infections could contribute to the
appearance of X4 strains during the symptomatic stage
[85].
HIV-suppressive β-chemokines
The beta-chemokines MIP-1α(CCL3), MIP-1β(CCL4),
and RANTES (CCL5) are the natural ligands of CCR5. Two
additional variants named CCL3L1 and CCL4L1, encoded
by genes arising from the duplication of CCL3 and CCL4,
respectively, have also been described [86]. The role of β-
chemokines in HIV infection was first proposed in a sem-
inal article in which the anti-HIV-1 effect of these mole-
cules was reported just a few months before the discovery
of CCR5 as co-receptor for HIV-1 [87]. Soon thereafter,
several reports found inverse correlations between the lev-
els of β-chemokines in plasma and the rate of disease pro-
gression [88,89]. Elevated levels of RANTES have also
been associated with protection against HIV transmission
in some EU cohorts [90]. Interestingly, no differences in
the plasma levels of beta-chemokines have been observed
in some EU cohorts. These individuals display normal lev-
els of CCR5 on their CD4-positive T cells. However, CD4-
positive T cells from these EUs appear more sensitive to
the HIV-1 inhibitory effect of β-chemokines, suggesting
the existence of yet unknown mechanisms influencing the
role of CCR5 in infection [91].
When bound to CCR5, β-chemokines induce internaliza-
tion of the receptor, abrogating its ability to promote HIV-
1 infection [92]. The mechanisms governing inter-individ-
ual variations in β-chemokine expression are not com-
pletely understood. In support of a role for β-chemokines,
SNPs in the MIP-1α gene are found at elevated frequencies
among EU individuals [93]. SNPs in the promoter regions
of the RANTES gene have also been described and they
could affect expression of RANTES. However, their role in
disease progression remains controversial [94].
CCL3L1, also known as MIP-1αP, is the more potent
CCR5 agonist and the strongest inhibitor of infection by
R5 HIV-1 strains [95]. Interestingly, the levels of CCL3L1
are determined, in part, by the number of tandem copies
of the CCL3L1 gene, which varies from 2–10 among indi-
viduals, with highest copy numbers found in African pop-
ulations [96]. When analyzed by itself, the number of
CCL3L1 copies is not significantly associated with HIV
susceptibility. However, significant trends are found when
the number of copies is analyzed in the context of a spe-
cific population. Thus, people with higher number of cop-
ies than their ethnic background average are less
susceptible to HIV-1 infection and progress slower to
AIDS [96]. These findings underscore the important role
of CCL3L1 in disease progression.
Another study has revealed a role for MIP-1β in HIV-1
pathogenesis [97]. This chemokine is encoded by two
highly related genes (CCL4 and CCL4L1). Two polymor-
phisms of the CCL4L1 gene have been described (L1 and
L2). Individuals homozygous for L2 display reduced lev-
els of CCL4 transcripts when compared to homozygous
for L1. A higher frequency of the L2 allele has been
observed in a Spanish cohort of HIV-infected patients, as
compared to healthy controls, suggesting that the levels of
MIP-1β may influence HIV-1 susceptibility [97]. Polymor-
phisms in the RANTES gene have also been reported. Ele-
vated levels of circulating RANTES are common in EU
individuals and in HIV-seropositive patients displaying
slow progression (reviewed in [98,99]). Two changes in
the promoter (-403G/A and -28C/G) appear to modulate
in vitro transcription of RANTES. In vivo, the presence of
the -403A and -28G haplotype has been associated with
slower disease progression in Japanese and Thai cohorts
[100,101], and lower susceptibility to infection in a Chi-
nese cohort [102]. A second study has analyzed only the -
403A allele, confirming its protective role in HIV progres-
sion, but also describing it as a risk factor for HIV trans-
mission [103]. Thus, the role of polymorphisms in the
RANTES promoter remains controversial, with at least two
other reports failing to confirm these associations in Span-
ish cohorts [94,104]. The reason for these discrepancies
may be due to the quite different distribution frequencies
of RANTES alleles across ethnic groups. Further compli-
cating the study of RANTES polymorphisms, some alleles
appear to mitigate the effect of others. Thus, the -28G
allele, common in Asians, rare in Euopean-Americans
(EA) and absent in Africans, mitigates the disease-acceler-
ating effects of another RANTES variant, In1.1.C, which
have been described in EAs [105]. This latter allelic variantRetrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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by itself potently down-regulates RANTES transcription
[106].
SDF-1 (also known as CXCL12) is the only known ligand
of CXCR4 [107,108]. As with β-chemokines and CCR5,
occupation of CXCR4 by SDF-1 induces internalization of
the receptor [109]. Both CXCR4 and SDF-1 are essential
during development, and knock out of either of these
genes leads to lethal phenotypes in mice [110,111]. Not
surprisingly, alleles leading to lack of expression of SDF-1
or CXCR4 have not been identified. Nevertheless, the role
of of SDF-1 and CXCR4 in the adult life, recirculating leu-
kocytes and hematopoietic precursors, may be less vital. A
polymorphism in the noncoding region of SDF-1 has
been reported (SDF1-3'A). In the homozygous form, the
presence of an A at position 801 has been associated with
slower progression to AIDS, as compared to heterozygous
or wild-type homozygous. The biological basis for this
association is not clear, since no differences in SDF-1 lev-
els have been observed [112,113]. A number of reports
have failed to confirm this association in other cohorts
[114-117]. Thus, it is not clear whether the SDF1-3'A var-
iant play a role disease progression.
Other chemokines such as MCP1 (CCL2), MCP3 (CCL7),
and eotaxin (CCL11) bind CCR2 and CCR3, but not
CCR5. Each of these chemokines have been associated
with HIV pathogenesis. It has been suggested that they
control migration of immune cells to sites of HIV-1 infec-
tion, thus contributing to virus propagation in vivo [118].
Table 1 summarizes the role of known variants of chem-
okine receptors and their ligands in HIV pathogenesis.
DC-SIGN
DC-SIGN is a mannose-binding, calcium-dependent lec-
tin that has been involved in transmission of HIV-1 from
dendritic cells (DC) to T lymphocytes, a phenomenom
named "trans-enhancement" (reviewed in [119,120]).
DC-SIGN is expressed on immature DCs and activated B
lymphocytes. Trans-enhancement requires binding of
HIV-1 particles to DC-SIGN via the high mannose glycans
present in gp120. The mechanism of transfer of HIV-1 to
T cells remains controversial. First, it was proposed that
transfer requires internalization and transient storage of
HIV-1 particles in subcellular compartments [121]. Recent
evidence suggests that infection of DC cells is required for
efficient transfer of HIV-1 to other cells [122].
DCs are thought to be among the first cells infected by
HIV on the genital mucosa. Infected DCs migrate to
lymph nodes where they transfer viruses to T cells. By
infecting the very same cells implicated in protection
against infection in mucosal tissue, HIV-1 utilizes DCs as
Trojan horses that spread the virus to the lymph nodes.
The role played by DCs in facilitating infection suggests a
possible role for DC-SIGN variants and other C-type
lectins in HIV-1 disease progression and transmission. A
polymorphism in the DC-SIGN promoter at positions -
336 has been identified. Individuals at risk of HIV carrying
the -336C allele are more susceptible to infection than
persons with the -336T variant [123]. This association,
however, has been observed for parenteral transmission
of HIV-1, but not for mucosally acquired infection. Vari-
ants in the coding region of DC-SIGN and DC-SIGNR
have also been identified. However, the importance of
these alleles in protecting from HIV-1 infection has yet not
been fully elucidated [124-126].
Langerin, also called CD207, is selectively expressed in
Langerhans cells, which are spread over the mucosa
through which HIV transmission occurs. Under some
experimental conditions, Langerhans cells are infected
with HIV-1 and transmit virions to T cells [127]. However,
recent evidence suggests that Langerin, in contrast to DC-
SIGN, prevents HIV-1 transmission. HIV-1 particles cap-
tured by Langerin are internalized and degraded into
Birbeck granules [128]. Thus, Langerhans cells appear to
present a first barrier against infection. This study does not
exclude the possibility that these cells transmit HIV-1 at
high viral inocula [129]. The role of Langerin variants in
HIV-1 transmission has not been studied, although a
mutation in the langerin  gene in a person deficient in
Birbeck granules has been described [130].
In addition to DC SIGN, other C-type lectin receptors may
also act as receptors for HIV-1: DC-SIGN-related (DC-
SIGNR), the mannose receptor (MR), and Langerin can
also bind gp120 [120].
Anti-HIV-1 activity of human defensins
Defensins are small antimicrobial and antiviral cysteine-
rich cationic peptides produced by leukocytes and epithe-
lial cells. The role of defensins in innate immunity to fight
bacterial, viral and fungal infections has long been known
[131,132](reviewed in [133-135]). The first report on the
anti-HIV-1 activity of defensins dates back to 1993 [136].
Mammalian defensins are classified into alpha-, beta-,
and theta defensins, and differ in their size and distribu-
tion of disulfide bridges [135]. Alpha and β-defensins are
peptides typically composed of 30–45 residues, and both
display anti HIV-1 activity [135]. Theta-defensins are
cyclic peptides composed of two alpha-like precursor pep-
tides. Active theta-defensin products are found only in
some non-human primates, and are typically composed
of 16–18 residues [137]. Given their smaller size theta-
defensins have been included in the family of minide-
fensins, which include molecules also found in other spe-
cies such as horseshoe crabs and spiders [138]. In humans
and chimpanzees theta-defensins are found only as inac-Retrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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Table 1: Chemokine and chemokine receptor variants modulating HIV transmission and pathogenesis
Gene Allele or factor Mode Effect Mechanism of 
action
Frequency(1) References
Chemokine 
Receptor
CCR5 ∆32 Recessive Resistance to 
infection
Truncated co-
receptor is not 
expressed at the 
cell surface.
Caucasians (4–
15%)
25, 30, 31
CCR5 ∆32 Dominant Delay AIDS Reduced co-
receptor 
expression.
Caucasians (4–
15%)
38–41
CCR5 C20S Dominant Prevent HIV 
infection in the 
presence of ∆32
Very low co-
receptor 
expression. Loss 
of disulfide bridge, 
improper folding?
Caucasians (0.3%) 49, 51
CCR5 A29S Unknown (2) Not evaluated Failure to bind 
RANTES, MIP-1β 
and MIP-1α
Africans (1.5%) 49,51
CCR5 R60S Unknown (2) Not evaluated Poor co-receptor 
internalization
Africans (1.3%) 51
CCR5 C101X Dominant Prevent HIV 
infection in the 
presence of ∆32
Truncated co-
receptor not 
expressed at cell 
surface
Africans (1.4%) 49, 51, 52
CCR5 G106R Unknown(2) HIV resistance/
Delay AIDS?
Very low co-
receptor 
expression
Asians (1.4%) 50
CCR5 C178R Unknown(2) HIV resistance/
Delay AIDS?
Very low co-
receptor 
expression
Asians (0.5%) 49
CCR5 C269F Unknown(2) HIV resistance/
Delay AIDS?
Very low co-
receptor 
expression. Loss 
of disulfide bridge, 
improper folding?
Asians (1.4%) 49, 50
CCR5 FS299 Unknown(2) No effect on HIV 
transmission
Truncated co-
receptor, poorly 
expressed
Asians (4%) 49
CCR5 P1 (promoter 
haplotype)
Recessive Accelerate AIDS Increase CCR5 
expression?
Unknown 53
CCR5 59029-A/A 
(promoter)
Recessive Accelerate AIDS Increase CCR5 
expression
Caucasians (57%) 54
CCR2 64I Dominant Delay AIDS in 
some cohorts
Influence CCR5 or 
CXCR4 
expression?
General (10–20%) 62, 64, 66, 67
CX3CR1 I249/M280 Recessive Accelerate AIDS? Influence 
recruitment of 
immune cells?
Caucasians (I249: 
26%; M280: 14%)
69, 71
Chemokine
MIP-1αP 
(CCL3L1)
Gene copy 
number
Increase 
susceptibility to 
infection
Copy number 
correlates with 
levels of CCR5 
agonist. Block HIV 
entry
Africans (5–7 
mean copy 
number)
96
MIP-1β(CCL4L1) L2 Dominant Increase 
susceptibility to 
infection
Reduced level of 
MIP-1β
Caucasians (16%) 97
RANTES (CCL5) -403A (promoter) Dominant Delay AIDS Up-regulate 
RANTES 
transcription
Asians (27%) 100–102Retrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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tive pseudogenes. These pseudogenes are transcribed into
mRNAs, but they harbor premature stop codons that pre-
clude expression of functional products. Interestingly,
when the putative human ancestral gene for a human
theta-defensin was reconstituted, it was found to display
in vitro potent anti-HIV-1 activity against R5 and X4
strains [139]. The artificially reconstituted product was
named human retrocyclin-1. This molecule displays lec-
tin-like properties and binds to CD4 and gp120, thus pre-
venting entry of HIV-1 into target cells [140].
So far six human α-defensins (also known as human neu-
trophil peptides or HNP) have been identified. α-
defensins also bind CD4 and the viral envelope glycopro-
tein. Treatment of permissive cells with α-defensins
induces down-modulation of CD4 [141]. Additionally, in
the absence of serum (e.g. at mucosal surfaces), α-
defensins may inactivate virion particles by a mechanism
that includes membrane disruption [142]. These findings
indicate that α-defensins block HIV-1 entry at several
steps, by directly inactivating virions and by blocking or
eliminating the viral receptor from the cell surface. The
mechanism of action of α-defensins and their inhibition
profile led researchers to suggest that these molecules
could constitute the long-sought CD8-positive cell anti-
HIV factor (CAF) [143]. The existence of CAF was first sug-
gested in 1986, as a soluble factor derived from CD8-pos-
itive cells in LTNP individuals with the ability to achieve
durable immune responses controlling HIV-1 infection
[144]. A report in 2002 suggested that based on specific
antibody recognition, α-defensins 1, 2, and 3 were
responsible for the antiviral activity of the eluded CAF fac-
tor. Experiments demonstrated that CAF activity could be
eliminated with anti-α-defensins antibodies, and α-
defensins could be detected inside CD8-positive cells
[143]. Later reports failed to confirm these results and
found no evidence for the production of α-defensins in
CD8-positive cells, although CD8-positive cells may inter-
nalize α-defensins. However, it is not clear whether the
uptake of these molecules is needed for their function
[145,146]. Beta-chemokines produced by CD8-positive
cells may also contribute to the activity of CAF, which may
no longer be ascribed to a single host factor. It is likely that
CD8-positive cells express an unknown array of novel
HIV-suppressive factors. Thus, the search to elucidate the
CAF factor activities is still ongoing.
Six human β-defensins have been identified in epithelial
cells, although genomic searches indicate that up to 28
different genes may be present in humans [147]. The
mechanism of action of β-defensins shares some similari-
ties with that of α-defensins. They block viral entry of both
X4- and R5-tropic HIV-1 strains, although their effect is
more potent with T-tropic isolates. Beta-defensins 2 and 3
achieve their inhibitory effect in part by direct inactivation
of viral particles, and also by down-modulation of
CXCR4, but not CCR5, on T cells [148]. This latter mech-
anism, however, has not been confirmed by others [149].
Interestingly, HIV-1 induces expression of human β-
defensins 2 and 3, but not 1, the latter of which displays
poor antiviral activity. Induction of these defensins occurs
by a mechanism that does not require viral replication
[148,150,151]. Recent findings suggest that β-defensin 2
may mediate its effect via CCR6. Beta-defensin 2 binds
CCR6, and its inhibitory effect is abrogated after treat-
ment of cells with anti-CCR6 antibodies. In agreement
with this, MIP-3-α(also known as CCL20), the cognate
ligand for CCR6, blocks HIV-1 infection in a manner sim-
ilar to β-defensin 2 [152]. CCR6 is not a co-receptor for
HIV-1, but is expressed in CD4+CD45RO+CCR5+ lym-
phocytes and dendritic cells, where it may play an impor-
tant role governing the movement of immune cells to
mucosal surfaces, the first tissues encountered by HIV dur-
ing sexual transmission. Thus, β-defensins may also con-
trol HIV-1 replication by modulating the immune system.
The mechanisms of defense against HIV infection medi-
ated by α-, β-, and θ-defensins are summarized in Table 2.
The demonstrated antiviral activity of defensins have
encouraged the search for polymorphisms influencing
HIV-1 infection and disease progression. Both, α-, and β-
defensins have been found in human breast milk, suggest-
RANTES (CCL5) -28G (promoter) Dominant Delay AIDS Up-regulate 
RANTES 
transcription
Asians (8%), rare 
in Caucasians
100–102
RANTES (CCL5) In1.1C (intronic) Dominant Accelerate AIDS Down-regulate 
RANTES 
transcription
General (14–17%) 106
SDF-1 (CXCL12) 3'A Recessive Delay AIDS? Unknown. Asians (25–35%) 
Oceanian (50–
70%)
112, 113
MCP1/MCP3/
Eotaxin
H7 haplotype Dominant Decrease 
susceptibility to 
infection
Unknown 
immunomodulator
y effects
Caucasians (19%) 118
(1) Allele frequency in populations in which the variant is more predominant. (2) No homozygous individuals have been identified
Table 1: Chemokine and chemokine receptor variants modulating HIV transmission and pathogenesis (Continued)Retrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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ing that they could play a role in protecting infants from
infection [153,154]. One study has associated the amount
of α-defensins in breast milk with protection against intra-
partum and postnatal transmission of HIV-1 [155]. SNPs
in the 5'-untranslated region of the human β-defensin 1
gene (DEFB1) have been associated with HIV-1 infection
in an Italian pediatric cohort. The presence of a C/C allele
at position -44 in HIV-1 infected mothers and their chil-
dren is associated with higher risk of maternal-fetal trans-
mission [156,157]. These results have been confirmed by
the same group in another cohort of Brazilian children
[158]. However, studies with HIV-1 infected adults are
still missing. Further highlighting the role of human
defensins in HIV pathogenesis, elevated levels of α-
defensins have been reported in EU individuals and HIV-
infected women, as compared to healthy controls [159].
Interestingly, human genes for both α-defensins (DEFA1
and DEFA3), and β-defensins (DEFB4, DEFB103, and
DEFB104) are known to be polymorphic in copy number
[160-162]. Transcription of these genes correlates with
copy number, and it is tempting to speculate that, as dem-
onstrated for the CCL3L1 and CCL4L1 chemokines, poly-
morphisms in the copy number of defensin genes may
modulate HIV-1 susceptibility and disease progression.
Host factors modulating early post-entry events 
of HIV-1 replication
Cyclophilin A and TRIM5α
Studies in the early '80s identified cyclophilin A (CypA) as
a cytosolic protein binding to the immunosuppressant
molecule cyclosporin A [163]. Subsequent studies identi-
fied an anti-HIV activity of cyclosporin A [164,165],
although its mechanism of action was not elucidated at
that time. The role of CypA in HIV-1 replication was inves-
tigated in detail after discovering its HIV-1 capsid (CA)
binding properties in a yeast two-hybrid screen [166]. As
a result of this interaction CypA is incorporated into vir-
ion particles [167-169]. After years of studies the mecha-
nism of action of CypA has just begun to be unraveled.
HIV-1 has a limited host range that appears to be
explained in part by the existence of saturable inhibitory
factors that block virus replication at early steps, before
reverse transcription occurs [170-172]. CypA promotes
HIV-1 infectivity in target cells by a mechanism that does
not require CypA incorporation into virions [173,174].
The exact mechanism of action remains an enigma. CypA
appears to modulate the action of other restriction fac-
tor(s), perhaps by altering CA conformation in a manner
that makes it less sensitive to their inhibitory effect
(reviewed in [175]). The nature of the proposed confor-
mational change may relate to the cis-trans isomerization
Table 2: Anti-HIV activity of human defensins
Defensins Regulation Cell Source Mechanisms References
α-Defensins
HNP1, HNP2, and HNP3 Constitutive HPN2 may be 
the product of proteolytic 
processing of HNP1/HPN3
Neutrophils and 
promyelocytes
• CD4 down-modulation
• Viral membrane disruption 
and binding to CD4 and 
gp120 (in absence of serum)
• Upregulation of CC-
chemokines in macrophages
• Block of nuclear transport 
(by HNP1)
131, 143, 146
HNP4 Constitutive Neutrophils • Unknown (lectin-
independent mechanism)
135
β-Defensins
HBD2 and HBD3 Inducible by HIV, 
opportunistic infections, and 
pro-inflammatory cytokines 
(TNF, IL-1B)
Epithelial cells, monocytes, 
monocytes-derived DCs, 
macrophages, and 
keratinocytes
• Viral membrane disruption 
(absence of serum)
• CXCR4 down-modulation
• CCR6-mediated 
chemotactic effects
148–151
θ-Defensins
Retrocyclins (RTD1, RTD2) Synthesis blocked in humans 
by premature termination 
codon
RNA transcripts, not 
protein, expressed in 
bone marrow
• Prevent HIV entry by 
binding to CD4 and gp120
138–140Retrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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of peptidyl-prolyl bonds mediated by CypA. However, the
significance of this activity has not been conclusively
demonstrated [176]. Interestingly, cyclophilins may con-
stitute modulators of the innate immune response in
other eukaryotic systems. Recently, an innate mechanism
of defense against Pseudomonas syringae infection has been
described in Arabidopsis. Upon infection, a plant cyclophi-
lin activates a bacterial protease, which then triggers a cas-
cade of events that activates a plant's defense response
[177]. Thus, cyclophilins may represent evolutionarily
conserved mechanisms of innate defense.
Several SNPs have been identified in the human CypA
gene (PP1A). Their associations with HIV-1 infection and
disease progression in vivo have not been studied to date.
However, one group has used an ex vivo approach to eval-
uate polymorphisms in PP1A. In this strategy, CD4 T cells
were purified from healthy donors and challenged in vitro
with HIV-1. The extent of viral replication was correlated
with specific alleles, and when in vivo data is available,
correlations with disease progression in a cohort of HIV-1
infected individuals were sought. Following this approach
a polymorphism in the PP1A promoter (1650A/G) was
associated with lower ex vivo virus replication in cells
derived from PP1A homozygous individuals (AA), and
slower disease progression in vivo [12]. The ex vivo repli-
cation profile in cells carrying alleles previously associated
with slow progression (CCR5∆32 and CCR264I) or rapid
disease progression (RANTES In1.1C) followed the
expected trend, confirming the validity of this ex vivo
approach to identify relevant alleles. Nevertheless, valida-
tion studies with other cohorts will be needed to define
the role of CypA variants in HIV-1 pathogenesis.
Another cellular factor implicated in early steps of HIV-1
replication is TRIM5α. This protein was identified from a
rhesus macaque library screened for simian factors
restricting HIV-1 replication upon transfer into otherwise
permissive human cells [178]. Early studies suggested that
the action of TRIM5α and CypA were somehow related,
and as mentioned above, it was suggested that CypA pro-
tects CA from the deleterious effects of human TRIM5α
[175]. TRIM5α also binds HIV-1 CA, though apparently in
a CypA-independent manner [179-181]. An alternative
model proposes that common restriction factors may be
shared in the cascade of events that leads to inhibition of
HIV-1 replication by TRIM5α, and promotion of infectiv-
ity by CypA [175].
Unlike simian forms, the human ortholog of TRIM5α
appears to only modestly inhibit HIV-1 replication. This
has led to the hypothesis that polymorphisms in the
human TRIM5α gene might result in increased restriction
and modulate HIV-1 infection. One recent report has
identified a TRIM5α haplotype (hap 9) containing a non-
synonymous SNP at position 136 (R136Q) that occurs
with higher frequency among HIV-infected subjects than
in exposed seronegative individuals [182]. None of the
individual SNPs found in this haplotype influenced HIV
transmission, suggesting that the genetic sequence
responsible for the observed phenotype is in linkage dise-
quilibrium with this haplotype, lying in TRIM5 or one of
the TRIM genes adjacent to it. Another study evaluated the
136Q allele and found the frequency of this allele elevated
in uninfected African-Americans, as compared to HIV-1
infected subjects. However, this correlation was not
observed in individuals of European descent. In agree-
ment with a role for TRIM5α, the 136Q variant exhibited
slightly stronger inhibitory activity than the 136R counter-
part [183]. The same study reported the identification of
two additional non-coding SNPs present in one TRIM5α
haplotype that is found in HIV-1 infected patients at
higher frequencies than in uninfected individuals. The
above studies suggest that polymorphisms in TRIM5α
may influence susceptibility to HIV-1 infection. Only one
study has evaluated the role of common TRIM5α variants
on disease progression. The authors analyzed a cohort of
979 HIV-infected patients and found only modest associ-
ations with the rate of CD4-positive T cell decline before
the onset of treatment [184]. The viral determinants for
sensitivity to inhibition by TRIM5α lie in the viral CA
region. In vitro, mutations in HIV-1 CA overcome the
restriction of HIV-1 to replicate in simian cells. A study by
the Schuitemaker group has evaluated the presence of
TRIM5α escape mutants in HIV-1 infected individuals, as
an indicator of TRIM5α-mediated inhibition. Interest-
ingly, CA escape mutants emerging late in the infection
process could be found in 14% of the infected patients
(N.A. Kootstra and H. Shuitemaker, personal communica-
tion). These findings suggest the existence of selective
pressure on the virus to avoid TRIM5α-mediated restric-
tion.
The innate immune response mediated by APOBEC3G
Host cells are endowed with another mechanism to halt
HIV-1 infection before integration occurs. The human
apolipoprotein B mRNA-editing enzyme-catalytic
polypeptide-like-3G (APOBEC3G), formerly known as
CEM15, is an endogenous inhibitor of HIV-1 replication
[185-187]. In the absence of the viral protein Vif,
APOBEC3G is incorporated into HIV-1 particles in the
producer cell, and during reverse transcription deami-
nates cytosine bases to uracil in the negative-sense single-
stranded DNA, resulting in G to A hypermutations in the
complementary, positive sense DNA strand. This hyper-
mutation leaves the viral cDNA vulnerable to degradation
by nucleases. Those cDNAs that manage to integrate into
the host chromosomes carry multiple mutations that
likely result in aberrant viral products [188-190]. Recent
reports appear to suggest that APOBEC3G also exerts anti-Retrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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viral activities through mechanisms independent of its
cytidine deaminase activity [191,192]. APOBEC3G can be
found in cells in two different forms of low and high
molecular-mass (LMM and HMM, respectively).
APOBEC3G in LMM form is enzymatically active and
restricts HIV-1 infection. The HMM form is a catalytically
inactive ribonucleoprotein complex that appears to pro-
tect against mobilization of endogenous cellular retroele-
ments such as Alu and hY [193-195]. Endogenous
retroelements can influence transcription of adjacent
genes and induce genetic disease in humans by insertional
inactivation [196-198]. This APOBEC3G-induced mecha-
nism of restriction of Alu and hY mobilization is medi-
ated by sequestration of the RNA retroelements into
HMM complexes, which are kept away from the L1-
dependent retrotransposition machinery [193].
APOBEC3G and related deaminases may also protect
against other retroviruses and hepatitis B virus, which also
relies on a reverse transcription step to complete its life
cycle [186,191].
The Vif protein binds APOBEC3G in virus producer cells
and targets it for degradation in the proteasome, thus pre-
venting APOBEC3G incorporation into virions [199-201].
To induce APOBEC3G degradation Vif binds the cellular
proteins Cul5, elonginB, elonginC and Rbx1, to form a
cullin5-based E3 ubiquitin ligase complex that leads to
polyubiquitination and ultimately to proteasomal degra-
dation of APOBEC3G and APOBEC3F, which also dis-
plays anti-HIV activity [200,202].
The importance of the APOBEC3G-mediated innate
response against HIV-1 is underscored by the existence of
both APOBEC3G and Vif genetic variants influencing dis-
ease progression. Studies with LTNP have revealed an
association between low viral load and a serine residue at
position 132 of Vif. When tested in vitro, HIV-1 carrying
Ser132 displayed a five-fold decrease in replication in
PBMC, as compared to virus containing the wild type
allele (Arg) at the same position [203]. Another study
revealed the presence of a two-amino-acid insertion in the
Vif protein of a mother's virus and her child's, both LTNP.
This amino acid insertion results in an aberrant Vif pro-
tein that severely impairs replication when expressed in a
recombinant HIV-1 [204]. Furthermore, Vif-defective pro-
teins have been isolated from strains from other LTNP
individuals [205]. The reason why some of these LTNP Vif
variants do not revert to encode a functional product is
not understood. It is possible that Vif plays other roles in
viral replication that constrain its ability to mutate. Alter-
natively, the genetic background of these LTNPs may have
weakened the virus' ability to replicate and mutate in
these subjects.
With regards to APOBEC3G, it is plausible that genetic
variants with altered inhibitory activity or partially resist-
ant to Vif might alter the course of HIV-1 disease. A variant
of APOBEC3G common in African-Americans has been
identified, which contains a non-synonymous substitu-
tion. This allele carries Arg instead of His at position 186
(186R) and is strongly associated with faster decline of
CD4 T cells and accelerated progression to AIDS [206].
This variant, however, appears to have the same in vitro
inhibitory activity than the common 186H allele. An
extensive analysis of a French cohort failed to identify sig-
nificant associations between 29 APOBEC3G polymor-
phisms and disease progression, although discrepancies
with previous studies may be explained by the different
variables used to analyze disease progression [207].
Another study identified an APOBEC3G variant
(C40693T) in a cohort of EU Caucasians subjects. This
allele was found to be strongly associated with increased
risk of infection [208]. A recent report revealed an inverse
correlation between APOBEC3G mRNA levels and viral
load in infected individuals, with the highest APOBEC3G
levels observed in LTNP patients [209]. However, no asso-
ciations with specific variants in the APOBEC3G gene
have been identified in these individuals. The controversy
over APOBEC3G variants, and the lack of a potential
mechanism to explain their phenotypes warrants the need
for additional studies.
A recent study has evaluated polymorphisms in the CUL5
gene encoding the Cullin 5 protein. Haplotypes encom-
passing 12 SNPs were clustered into two different groups
that segregated with different profiles of CD4 T cell
decline rates and viral load [210]. One individual SNP
(SNP6 A/G) appears responsible for the rapid CD4 T cell
depletion and progression to AIDS. This correlation was
observed in African-Americans, but not found in Euro-
pean-American and Asian populations. Interestingly, a
significant additive effect was observed between some of
the SNPs found in CUL5 and the APOBEC3G-186H allele.
This study highlights the role of Cullin 5 in HIV-1 patho-
genesis. Additional studies will be needed to understand
the roles of CUL5 variants. Table 3 summarizes the effect
on HIV infection and progression to AIDS of known
genetic variants of human genes participating in post-
entry steps of the virus life cycle.
Cellular factors modulating late steps of HIV-1 
replication
The final steps of HIV-1 replication involve viral assembly
and the release of new progeny. HIV-1 encodes the viral
protein U (Vpu), which facilitates viral release from
infected cells. Vpu appears to overcome the inhibitory
effect of cellular factor(s) blocking viral budding
[211,212]. The identity of this factor remains elusive.
Recent evidence suggests that this factor may redirect HIV-Retrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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1 particles to an endocytic route, a phenomenon that is
overcome by expression of Vpu [212]. Some studies have
suggested that Vpu may act by counteracting the potas-
sium channel TASK-1, which interferes with the release of
retroviruses by unknown mechanisms [213,214]. Vpu is
also known to interact with βTRCP, a component of a
cullin1-based E3 ubiquitin ligase. Interaction between
Vpu and βTRCP targets CD4 for proteasomal degradation,
contributing to virus-induced down-modulation of CD4.
By binding to βTRCP, Vpu also inhibits the βTRCP-
dependent degradation of IκB, which results in suppres-
sion of NF-κB and induction of apoptosis in infected cells
[215,216]. Therefore, it is plausible that the levels of these
proteins or polymorphisms in cellular genes implicated in
Vpu function modulate HIV-1 susceptibility and disease
progression in vivo.
The cellular determinants responsible for assembly and
release of HIV-1 have been extensively documented in the
last five years. TSG101 (tumor susceptibility gene 101)
encodes a host cellular protein required for HIV-1 bud-
ding. The PTAP "late domain" found in the P6 product of
HIV-1 Gag recruits TSG101 (also known as VPS23) to
facilitate virus budding [217-219]. In uninfected cells
TSG101 functions in the biogenesis of the multivesicular
body (MVB), which is required for the sorting of mono-
ubiquitinated transmembrane proteins into internal vesi-
cles. HIV-1 P6, through its interaction with TSG101,
usurps the cellular machinery to promote viral budding at
the plasma membrane in T cells and macrophages [220-
222](reviewed in [223,224]). TSG101 is a component of
the ESCRT-1 complex (endosomal sorting complex
required for transport), and is known to bind multiple
components of the MVB machinery (VPS28, VPS37, AIP1,
Hrs, TOM1L1, EAP30, EAP45, and GGA proteins). At least
eleven different human proteins have been shown to
modulate HIV-1 budding (TSG101, VPS28, VPS37C,
CHMP2A, CHMP3, CHMP4B, CHMP4C, VPS4A, VPS4B,
AIP1, and Tal), and it is likely that many other compo-
nents of the MVB pathway participate in this step of the
viral cycle [223-228].
A few studies have evaluated polymorphisms in TSG101.
One study utilized an ex-vivo/in vivo approach to evalu-
ate a SNP in the noncoding region of the tsg101  gene
(position -183). The presence of C at this position
(instead of T) results in a dominant effect that signifi-
cantly reduces replication of HIV-1 in vitro [12]. Paradox-
ically, the same allele leads to faster disease progression
(measured as CD4 cell count decline). Thus the role of
this variant in HIV pathogenesis remains unclear
[12,229].
Table 3: Human genes modulating HIV pathogenesis by influencing post-entry steps of the viral life cycle
Gene Allele or factor Mode Effect Mechanism of 
action
Frequency(1) References
CypA (PP1A) 1650 G Recessive Delay AIDS Unknown Unknown 12
TRIM5α Haplotype 9 Increase HIV 
transmission
Unknown Caucasians (1%) 182
TRIM5α 136Q Dominant Protect against 
HIV infection
136Q variant 
displays stronger 
anti-HIV activity
African Americans 
(20%)
183
TRIM5α 43Y Dominant Protect against 
HIV infection
Unknown African Americans 
(6.5%)
183
APOBEC3G 186R Recessive Accelerate AIDS Unknown African Americans 
(36.7%)
206
APOBEC3G C40693T Unknown Increase HIV 
transmission
Unknown (variant 
found in intronic 
region)
Caucasians (< 1%) 208
Cullin5 SNP6 A/G Dominant 
(additive)
Accelerated CD4 
T cell depletion 
and AIDS 
progression
Unknown (the 
SNP6 G product 
displays stronger 
binding to nuclear 
proteins
Africans (5%)(2) 210
TSG101 -183C Dominant Accelerated CD4 
T cell decline
Increase virus 
budding? 
(paradoxically the 
-183C variant 
reduces 
replication in ex-
vivo systems)
Caucasians (17%) 12, 229
(1) Allele frequency in populations in which the variant is more predominant. (2) Higher allele frequencies are observed in European Americans (10%) 
and Chinese (20%), however the correlation is not observed in these populations.Retrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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It has long been known that interferon-α, a key compo-
nent of the innate response against some viral infections,
interferes with HIV-1 particle release, however its mecha-
nism of action has remained unknown until recently
[230,231]. The interferon-induced ubiquitin-like protein
ISG15 appears to be a critical component of the inter-
feron-α antiviral response. ISG15 inhibits ubiquitination
of TSG101 and the late HIV-1 Gag domain, inhibiting the
P6-TSG101 interaction required for viral budding [232].
Another cellular factor regulating late steps of the viral
cycle is HP68 (also known as ABCE1 and RNase L inhibi-
tor). HP68 appears to be critical in the assembly of the
HIV-1 capsid proteins. HP68 interacts with the NC
domain of Gag, and as proteolytic processing of the Gag
polypeptide occurs, HP68 is released from these com-
plexes and viral particles acquire their mature conforma-
tion [233-235]. The role of HP68 in HIV pathogenesis in
vivo has not yet been evaluated.
The matrix region of HIV-1 Gag binds the delta subunit of
the adaptor protein complex 3 (AP-3). This interaction
appears to play an important role in particle assembly
[236]. Although its role in HIV pathogenesis has not been
studied, mutations in ADTB3A, which codes for the
beta3A subunit of AP-3, have been characterized in indi-
viduals with a rare form of Hermansky-Pudlak syndrome
[237]. These individuals present defects in the vesicular
trafficking pathways leading to formation of the melano-
somal compartment, and are characterized by the pres-
ence of oculocutaneous albinism.
Cellular factors incorporated into HIV-1 particles
Many cellular proteins known to play important roles in
HIV-1 pathogenesis are incorporated into virions. For
instance, CypA, APOBEC3G, TSG101, and VPS28, which
are required at different steps of the viral cycle, are encap-
sidated into virions [167,189,217,238]. Most cellular pro-
teins are incorporated into viral membranes in a passive
manner if they associate with areas of the cell membrane
through which the virus buds (reviewed in [239]). How-
ever, some proteins are specifically incorporated into viral
membranes through interaction with viral products. Spe-
cific incorporation of cellular proteins inside virions or
into viral membranes has generally been seen as sugges-
tive of a functional role in the HIV-1 life cycle. Thus, it is
expected that many other proteins known to associate
with virions play a role in HIV-1 transmission and disease
progression. Among these potential candidates are the
integral membrane-spanning intracellular adhesion mol-
ecule 1 (ICAM-1). ICAM-1 expression drastically
enhances HIV-1 infectivity, and makes virions more resist-
ant to neutralization with gp120-specific antibodies or
sera from HIV-infected patients [240-245]. Enhancement
of infectivity can be blocked with anti-ICAM-1 mAbs, and
is augmented in cells expressing higher levels of LFA-1, the
ICAM-1 receptor. These findings suggest that HIV-1 may
use an ICAM-1/LFA-1 dependent route to promote cellu-
lar entry and escape the humoral immune responses tar-
geting the viral envelope protein. The interaction between
ICAM-1 and LFA-1 may also play an important role in
infection of CD4-positive memory T cells, which are con-
sidered a latent reservoir of the virus [246]. Polymor-
phisms in the ICAM-1 gene have been associated with
susceptibility to a range of degenerative and inflammatory
diseases. However their role in HIV pathogenesis has not
been evaluated [247].
Specific incorporation into HIV-1 virions of host-derived
HLA-DR, β2-microglobulin and class I MHC molecules
has long been known [248,249]. However, the physiolog-
ical relevance of these associations is poorly understood.
Several explanations have been suggested. Interestingly,
immunization with HLA-DR and class I MHC proteins
confer protection against SIV infection, probably by gen-
erating class-I and class-II-specific antibodies [250,251].
Additionally, incorporation of HLA-DR, one of the most
abundant cellular proteins, into viral membranes, renders
virions capable of stimulating purified T lymphocytes in
the presence of the staphylococcal enterotoxin A superan-
tigen [252]. Evidence that these mechanisms may influ-
ence HIV-1 pathogenesis is still missing, and these studies
should be interpreted with caution. It has also been sug-
gested that virion incorporation of MHC molecules could
enhance virus infectivity [239].
Other proteins specifically incorporated into lentivirus
capsids are hsp70, Ini1/SNF5, and the lysyl-tRNA syn-
thetase. Different roles in the viral life cycle have been
ascribed to these proteins. Hsp70 enhances the infectivity
of HIV-1 [253], whereas Ini1/SNF5 appears to modulate
virus yield and infectivity [254]. Lysyl-tRNA synthetase
may participate in the recruitment of tRNALys to prime
viral DNA synthesis [255-257]. The role of these proteins
in HIV-1 pathogenesis in vivo has not been addressed.
Host proteins modulating HIV-1 envelope incorporation
There is mounting evidence that the levels of envelope in
HIV-1 particles are finely modulated and could play an
important role in viral pathogenesis. Recent studies have
changed the common view of the HIV-1 virion. Initially,
it was believed that, like in other enveloped viruses, HIV-
1 viral membranes were abundant in envelope proteins. It
is now known that the relative density of envelope spikes
in HIV-1 virions is surprisingly low. Compared to influ-
enza, which contains 200–300 spikes per particle, it is
estimated that HIV-1 virions incorporate only 4 to 7
spikes per particle [258]. The reason for maintaining enve-
lope levels to a minimum is unknown, though it may beRetrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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related to the need to evade the antibody neutralizing
response directed against the viral envelope.
In HIV-1, specific signal sequences in the cytoplasmic and
membrane domain of gp41 modulate expression of enve-
lope at the cell surface. Interactions between the cytoplas-
mic domain of gp41 and the viral matrix protein
modulates envelope incorporation by a mechanism that
requires the cellular protein TIP47 [259-264]. The CD4
receptor, which plays an essential role allowing viral
entry, inhibits envelope incorporation late in the viral
cycle (reviewed in [265]). Excessive amounts of CD4 in
virus-producer cells interfere with envelope transport to
the cell surface, preventing its incorporation into viral
membranes [266,267]. Additionally, CD4, which is nor-
mally excluded from viral membranes, is then incorpo-
rated into HIV-1, interfering with the ability of envelope
to bind CD4 in target cells. To overcome the inhibitory
effects of CD4, HIV-1 utilizes three viral products, Nef,
Vpu, and Envelope, to ensure CD4 is removed after its
function in viral entry has been performed [265,268,269].
The importance of CD4 down-modulation in HIV-1 repli-
cation has been highlighted in recent studies. Nef-medi-
ated CD4 down-regulation correlates with the ability of
HIV-1 to replicate in blood-derived primary lymphocytes
and human lymphoid tissue [270-272]. Other studies
have evaluated the Nef-dependent CD4 down-modula-
tion activity through different stages of disease. Nef alleles
isolated from late symptomatic stages are more potent
CD4 down-modulators than alleles isolated from the
chronic asymptomatic stage [273,274]. This enhanced
activity translates in faster HIV-1 replicative properties in
vitro, and presumably in enhanced pathogenicity in vivo.
Many other studies have revealed the existence of muta-
tions or deletions in nef  genes isolated from LTNP
patients. In some instances, these changes have been asso-
ciated with diminished CD4 down-modulation activity
[275-278].
No enzymatic activities have been associated to HIV-1
Nef, and it is widely accepted that this viral product exerts
its CD4 down-modulation activity by binding to host pro-
teins. Nef is known to interact with more than 25 cellular
proteins. The physiological relevance of these interac-
tions, however, has not always been evaluated [279].
Despite the potential role of cellular partners involved in
Nef activities, to date no studies evaluating their influence
in HIV-1 pathogenesis have been performed.
Host factors modulating the innate immune response 
against HIV-1 infection
The cytokine system and its role in immunity against HIV-1
Cytokines play an important role in controlling the home-
ostasis of the immune system and the response against
pathogens. The role of IL-1, IL-2, IL-4, IL-6, IL-10, IL-16
and IL-18 in HIV-1 disease progression has been amply
documented, as have IFN- α, IFN-β, TNF-α, and TNF-β.
With regards to HIV infection, cytokines can be grouped
into HIV-inducing (TNF- α, TNF-β, IL-1, and IL-6), and
HIV-suppressive (IFN-α, IFN-β, and IL-16). IFN-gamma
and IL-4 display both stimulatory and anti-HIV effects
[280]. IL-1α and IL-1β are co-stimulatory cytokines for T
helper cells and promote maturation and clonal expan-
sion of B cells [281]. The role of the IL-1-dependent
inflammatory response has been highlighted by the iden-
tification of polymorphisms of the IL-1 receptor gene
(IL1Rα). The SNP IL1Rα-2134 has been found at higher
frequency in a French cohort of slow progressors [282]. IL-
2, a potent inducer of proliferation of antigen-primed T
lymphocytes, also plays an essential role in immune regu-
lation. Deficiency in IL-2 production is one of the first
immunologic defects described in HIV-1 infected individ-
uals [283]. Polymorphisms in the IL-2 gene have been
extensively analyzed in a study of HIV-seropositive Afri-
can-Americans [284]. A SNP deletion in a noncoding
region of IL-2 (IL2+3896) was associated with disease pro-
gression in homozygotic individuals.
IL-4 is a Th2 cytokine with co-stimulatory activity for T
and B cells. It has opposite effects on the HIV-1 co-recep-
tors, upregulating CCR5 and down-modulating CXCR4,
although it is not clear whether modulation of the HIV-1
co-receptors is sufficient to influence viral entry. Other IL-
4-dependent inhibitory effects in HIV-1 replication have
been documented, although these appear to be cell-
dependent and mostly affect X4-tropic strains. An IL-4
SNP (589T) known to influence transcription of the
cytokine has been associated with progression to AIDS in
some but not all studied cohorts [285,286]. Genetic stud-
ies of the IL-4 receptor alpha chain gene have also found
significant associations with disease progression and sus-
ceptibility to HIV-1 infection, although this latter pheno-
type appears to depend on the route of transmission
[287].
IL-16, a ligand for CD4, is a multifunctional cytokine. IL-
16 induces expression of class II MHC and displays chem-
otactic properties on CD4-positive T cells and monocytes.
IL-16 binds CD4 at an epitope distinct from from the HIV-
1 envelope binding site. The cytokine inhibits HIV-1 tran-
scription in T lymphocytes and monocytic cells [288,289].
Several studies have described the influence of IL-16 in
HIV-1 infection. The protective role of IL-16 appears to
occur at two different levels. First, IL-16 suppresses HIV-1
replication. Second, IL-16 facilitates immune reconstitu-
tion by enhancing expression of IL-2 receptors and mak-
ing T cells responsive to IL-2 [290]. Interestingly, T cell
clones from LTNP individuals express higher levels of IL-
16 than cells from AIDS patients [291]. Other clinicalRetrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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studies have found decreased levels of IL-16 as disease
progression advances [292,293]. Polymorphisms in the
IL-16 gene have been identified, but no associations with
HIV/AIDS have been reported to date [294].
IL-18 is a pro-inflammatory cytokine mostly secreted by
activated macrophages. IL-18 is known to play an impor-
tant role in responses against viruses and intracellular
pathogens. IL-18 induces IFN-γ production in T cells and
enhances NK cytotoxic activity. Increased levels of IL-18
have been found in late stage HIV-1 patients, and plasma
levels of this cytokine correlate with viral load, constitut-
ing an excellent marker for disease progression [295-297].
Several polymorphisms in the IL-18 gene are known, and
at least one SNP (IL18 C607A) has been associated with
increased risk of infection in a pediatric cohort [298,299].
Proteins of the interferon family play essential roles in the
innate response against viruses, including HIV-1. Type 1
interferons (IFN-α and IFN-β) induce expression of pro-
tein kinase R (PKR), which blocks protein synthesis in
virus-infected cells. IFN-α/β also enhance lytic activity of
NK cells, making them very effective in killing virally-
infected cells [300]. Polymorphisms in the IFN-α receptor
1 (IFNAR1) have been associated with disease progression
and susceptibility to HIV-1 infection [301].
Toll-like receptors
Another key family of proteins participating in the innate
immune response against pathogens is the Toll-like-recep-
tors (TLR) family. During HIV infection, TLRs may play an
important role in modulating the extent of viral replica-
tion (reviewed in [302,303]). There is mounting evidence
that in addition to direct activation of TLRs by HIV, indi-
rect activation mediated by opportunistic pathogens may
influence the outcome of disease [304,305]. Signals medi-
ated by pathogens can activate HIV transcription in trans,
via the production of proinflammatory cytokines such as
TNF-α, IL-1, or in cis, directly inducing expression of cel-
lular factors activating the viral LTR (NF-κB and AP-1)
[302].
Eleven TLR members have been identified so far in
humans [306]. TLRs recognize specific motifs expressed
by pathogens such as lipid moieties, protein motifs, and
nucleotide sequences. The first piece of evidence suggest-
ing a role for TLRs in HIV-1 pathogenesis dates back to
1990, when it was shown that bacterial LPS activates the
viral LTR, a process later found to be mediated by TLR4
[307]. To date, at least five TLR members (TLR2, TLR4,
TLR7, TLR8, and TLR9) have been implicated in induction
of HIV-1 expression during opportunistic co-infections
[308-313]. Several studies support a role for co-infecting
pathogens in HIV transmission and disease. TNF-α levels
are elevated in HIV-infected patients co-infected with
Mycobacterium tuberculosis [314]. In another report, a clin-
ical trial evaluating antisense molecules targeting HIV-1
Gag produced unexpected results, and revealed elevated
viral loads in treated patients. Several clues led the authors
to conclude that the unwanted effect had been the result
of TLR9 activation by CpG motifs present in the antisense
molecules [309,315,316]. Polymorphisms in the TLR9
gene have been associated with HIV-1 disease progres-
sion. Two SNPs (1635A/G and +1174G/A) are found at
higher frequency in HAART-naïve rapid progressors (esti-
mated as CD4 count decline) than in normal progressors
[317].
Further highlighting the influence of co-infecting patho-
gens, malaria episodes result in increased viral loads in
HIV-infected individuals, a factor that may have influ-
enced the spread of HIV in sub-Saharan Africa [318-320].
Likewise, a study of Kenyan pregnant women has shown
that susceptibility to malaria is enhanced up to 2-fold in
HIV-infected patients [321]. Interestingly, although
malaria did not significantly affect the frequency of
mother-to-child transmission according to this report, co-
infection with helminth parasites was associated with
increased risk of transmission by a mechanism likely
involving activation of intrauterine lymphocytes [321].
Importantly, not all co-infecting pathogens increase HIV
replication. Infections with GB virus, measles virus, Orien-
tia tsutsugamushi and HTLV type 1 and 2 viruses are known
to attenuate HIV infection [322]. Human herpesvirus 6
(HHV-6) and 7 (HHV-7) also suppress HIV replication.
Interestingly, these viruses inhibit infection with R5 tropic
strains, but minimally affect replication of X4 virus. HHV-
6 interferes with HIV-1 by upregulating the CCR5 ligand
RANTES [323]. Unlike HHV-6, HHV-7 exerts its effect by
downregulating CD4, the cellular receptor shared by
HHV-7 and HIV-1 [324]. The R5-specific effect of the inhi-
bition of HIV-1 replication by HHV-7 may be explained
by lower affinities for CD4 in R5 envelopes, as compared
to T-tropic envelopes.
The FC gamma receptor IIa (CD32) has also been shown
to influence HIV pathogenesis. This receptor is expressed
in B cells and monocytes, and plays an important role in
the removal of antibody-coated infectious agents [325].
One group has evaluated the effect of polymorphisms of
the FC gamma receptor IIa gene in HIV-1 perinatal trans-
mission in Kenyan women. The frequency of a His/
His131 SNP is higher in HIV-positive than in HIV-nega-
tive children, whereas distribution of an Arg/Arg131 allele
is reversed [326]. Another study with a Kenyan cohort
found similar conclusions for the same alleles in transmis-
sion of placental malaria [327]. Unlike the His131 form,
the Arg131 variant does not bind IgG2, however, further
experimental evidence is needed to evaluate whether thisRetrovirology 2007, 4:52 http://www.retrovirology.com/content/4/1/52
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property of the FC gamma receptor is responsible for the
observed phenotype.
Cytotoxic T lymphocytes (CTL) play an essential role in
the response to HIV infection. It is well accepted that the
efficacy of the CTL responses vary among infected individ-
uals and modulate disease progression in vivo [13,14]. In
addition to HLA variants, other molecules modulate the
efficacy of the CTL response. CTL-dependent killing of tar-
get cells is mediated by the content of storage granules
released near the junction of the CTL and target cell. These
granules contain the pore-forming protein perforin, and
several serine proteases called granzymes [328]. HIV-spe-
cific CTLs from LTNP achieving immunological control
proliferate extensively in response to autologous HIV-
infected CD4-positive T cells. These LTNP CTLs, unlike
those in normal progressors, express higher levels of per-
forin upon stimulation and proliferation with autologous
cells [329]. This suggests that the quality of the CTL
response plays an essential role in the response against
HIV infection. Supporting this, polymorphisms in the per-
forin gene have been associated with slower disease pro-
gression in a French cohort. The presence of the SNP
1012T in the proximal perforin promoter correlates with
fewer perforin-positive CTL cells, whereas homozygous
individuals (1012T/T) display a trend towards slower dis-
ease progression [330].
Conclusion
To date, considerable progress has been made in identify-
ing allelic variations associated with AIDS progression
and HIV-1 transmission. However, this work is beset by
problems. These include the polygenic and multifactorial
nature of the disease, and the difficulties in isolating the
effect of individual allelic variations in genetically diverse
cohorts of patients. The complexities of characterizing and
recruiting individuals for LTNP and EU cohorts, and the
genetic differences between ethnicities have also con-
founded the characterization of significant associations.
Despite this, it is anticipated that in the near future, the
map of genes involved in HIV-1 pathogenesis will be
greatly enhanced. Identification of these genes and the
variants associated with slow progression and resistance
to infection will allow physicians to predict better the out-
come of disease and to design antiretroviral regimes tai-
lored to patient-specific genotypes. As it has occurred with
the CCR5∆32 allele, the discovery of new variants might
invigorate the development of approaches to combat HIV-
1 infection. Furthermore, interpretation of clinical data
evaluating anti-HIV drugs and vaccines will also benefit
from an understanding of the effects of genetic predispo-
sition/resistance of the patients.
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